Liothyronine (T3, Cytomel)

In fitness circles, liothyronine often gets lumped in with “peptides” and “research chemicals.” It is neither. It is synthetic T3 — the more active of the body’s two main thyroid hormones — and it has been a legitimate, FDA-approved prescription drug under the brand name Cytomel since 1956. That history matters, because the honest story here is unusual: when it is dosed properly and monitored by a doctor, liothyronine has a reassuring safety record. Almost all of the danger comes from taking too much without supervision. This page is for education and harm reduction, and it contains no doses, cycles, stacks, or post-cycle protocols.

What it is

Liothyronine is a lab-made version of L-triiodothyronine (T3), the more active of your two main thyroid hormones (the other is T4, also called thyroxine). Cytomel is the long-standing US brand name (the drug itself is liothyronine sodium), and generic versions exist. It is a small-molecule hormone — not a peptide and not a steroid.

Here is how it works. T3 — whether you take it as liothyronine or your body makes it naturally by converting T4 — slips into your cells and then into the nucleus (the cell’s control center). There it latches onto thyroid hormone receptors (TRα and TRβ) sitting on your DNA, which act like switches for certain genes. Flipping those switches speeds up your metabolism: it raises your resting energy use, oxygen consumption, heat production, heart rate and pumping strength, and how fast you burn through fats and carbs. It also helps the brain and skeleton develop. The key difference from levothyroxine (T4) is speed: T3 is already in its active form, so it does not need to be converted first. That means its effects — on the heart and on metabolism — kick in within hours, and your blood levels and TSH (the hormone your brain uses to dial thyroid output up or down) swing up and down more sharply.

The claims

In medicine, liothyronine is mostly a backup option. The standard treatment for an underactive thyroid is levothyroxine (T4) on its own. T3 gets added to T4 for the minority of patients who still feel unwell on T4 alone, in some thyroid-cancer protocols that take advantage of how quickly it clears the body before a scan, and in myxedema coma (a rare, life-threatening thyroid emergency, where it is given by IV). Because T3 leaves the body fast and produces sharp peaks, it has to be dosed and monitored carefully — especially in older patients or those with heart trouble.

Among athletes and bodybuilders, T3 is used off-label and illegally, mainly as a fat-loss or “cutting” aid. The idea is to crank up the metabolism to get leaner, often before a competition. Some users wrongly believe it boosts the effects of anabolic steroids or offsets the metabolic slowdown that comes with dieting. This is non-medical use of a prescription drug, usually bought without a prescription.

What the evidence actually shows

On its core medical question, the human evidence is strong and consistent.

• Adding T3 to T4 (combination LT4+LT3) does not reliably beat T4 alone for an underactive thyroid. Many randomized trials and reviews show the combination does not reliably improve quality of life, mood, fatigue, or thinking compared with levothyroxine on its own for most patients. The Grozinsky-Glasberg 2006 meta-analysis (a study that pools many trials — here 11 trials and 1,216 patients) concluded that T4 alone should stay the treatment of choice, and a later review (Fischman & Domínguez 2018) found combination therapy “has minimal or no effect on fatigue and quality of life.” A subset of patients with stubborn symptoms may benefit, and some trials show improvement in selected individuals, but there is no proven benefit across the whole population.
• Properly dosed therapeutic LT3 looks safe. A 2025 JCEM meta-analysis (Bahl et al.) that pooled data from several sources covering roughly 13,000 LT3 users found no extra atrial fibrillation, a common irregular heartbeat (RR 1.10, 95% CI 0.74–1.63). Pooled together, those users actually had lower death rates than people on T4 only (RR 0.70, 95% CI 0.62–0.78) — though this is just an association and does not prove cause and effect. The crucial finding: serious harms were “almost exclusively linked to supratherapeutic LT3 exposure” — meaning above-therapeutic doses from compounding or dispensing mistakes, unregulated online buying, or misuse for weight loss and bodybuilding, often at “doses 10 to 1000 times above therapeutic levels.” That is the honest bottom line: at the right, monitored dose, LT3 appears safe; the danger is overdose and unsupervised use.
• No good case for performance enhancement. A 2022 JCEM review (Gild et al.) concluded that there is no real evidence of a performance benefit, that banning thyroid hormone in elite sport is “neither justified nor feasible,” and that too much thyroid hormone is more likely to hurt both health and performance.

Legal and regulatory status

In the United States, liothyronine/Cytomel is a prescription (Rx-only) drug and is not a DEA-controlled substance. It is legal to have with a valid prescription. Getting it or handing it out without one is against the law, but it is not a scheduled (tightly restricted) drug.

For honest comparison with other compounds in the “PED-support” space (PED meaning performance-enhancing drug):

• DNP (2,4-dinitrophenol) is not approved and is officially described as “unfit for human consumption” — the FDA banned it as a weight-loss agent in the 1930s. It is an industrial chemical with a long history of fatal poisonings, and it is sold illegally for fat loss.
• Mesterolone and fluoxymesterone are anabolic-androgenic steroids (lab-made versions of male hormones used to build muscle) and are Schedule III controlled substances under the Controlled Substances Act and the Anabolic Steroid Control Act (both are named specifically in 21 CFR 1308.13).

Anti-doping (WADA 2026). Thyroid hormones — liothyronine/T3 and levothyroxine/T4 — are not banned by WADA (the World Anti-Doping Agency), in or out of competition. WADA has repeatedly chosen not to ban them, pointing to the lack of believable evidence that taking extra thyroid hormone outside of a medical need actually improves performance (Gild et al. 2022). For the other named categories, aromatase inhibitors (S4.1), anti-estrogens/SERMs (S4.2), and insulins (S4.4, specifically S4.4.2, Insulins and insulin-mimetics) all sit within S4 (Hormone and Metabolic Modulators), while anabolic agents — including anabolic steroids such as fluoxymesterone and mesterolone — fall under S1. (The exact sub-section labels should be checked against the current 2026 List PDF before publishing.) The 2026 Prohibited List took effect January 1, 2026.

Safety

T3/liothyronine itself. Taken at label doses with monitoring, it has a reassuring safety record (the 2025 JCEM meta-analysis). The real risk is dose-driven thyrotoxicosis — the state of having too much thyroid hormone in your system. It is far easier to push the body into this state with T3 than with T4, because T3 is more potent, acts fast, and produces sharp peaks. Non-medical use creates a drug-induced (iatrogenic) thyrotoxic state with a suppressed TSH, and those harms are well documented:

• Heart problems and atrial fibrillation. Collet et al. 2012 (Thyroid Studies Collaboration, a meta-analysis that pooled individual records from 52,674 participants) linked having a mildly overactive thyroid to a higher risk of death from coronary heart disease (HR 1.29, 95% CI 1.02–1.62) and to new atrial fibrillation (HR 1.68, 95% CI 1.16–2.43), with the risk higher when TSH dropped below 0.10 mIU/L. A racing or pounding heart, angina (chest pain from reduced blood flow), and irregular rhythms are the main cardiac dangers — and in people who already have heart disease, these can tip into a serious cardiac event.
• Bone loss and fractures. Blum et al. 2015 (JAMA; Thyroid Studies Collaboration, 70,289 participants) found that a mildly overactive thyroid was tied to a higher fracture risk (any fracture, pooled HR ~1.28, 95% CI 1.06–1.53; hip ~1.36, 95% CI 1.13–1.64; spine ~1.51, 95% CI 0.93–2.45, which is not statistically significant, with the spine risk much higher when TSH was below 0.10). Too much thyroid hormone speeds up bone turnover and lowers bone density, especially in postmenopausal women.
• Other effects of too much thyroid hormone. Trouble tolerating heat and sweating, tremor, weight loss, muscle weakness, anxiety, and insomnia — and, with long-term suppression, a dampening of the body’s own thyroid control system (the HPT axis), which takes time to bounce back. The risk goes up with age, existing heart disease, and unsupervised “stacking” with stimulants or appetite suppressants (the very combination the boxed warning flags) or other PEDs.

For honest risk context — other compounds in this space:

• DNP — the most dangerous by far. It kills people. It jams the cell’s energy machinery (it uncouples mitochondrial oxidative phosphorylation), which makes the body throw off heat with no off switch, leading to fatal overheating (core body temperatures up to roughly 44 °C). There is no specific antidote or way to reverse it — doctors can only support the patient and wait. Deaths are well documented, and poison-center case series report roughly a 1-in-8 fatality rate among reported exposures. It is not a thyroid drug and is not safe to use in humans at all.
• Insulin (used by non-diabetics or without supervision): risk of severe, potentially deadly low blood sugar (hypoglycemia) — seizures, coma, brain injury.
• Aromatase inhibitors: lowering estrogen harms bone density and worsens cholesterol numbers, and can cause joint pain.
• SERMs (e.g., tamoxifen/clomiphene used as PED-support): a higher risk of dangerous blood clots (venous thromboembolism), plus vision problems and mood effects.

None of this is medical advice.

Bottom line

Liothyronine is synthetic T3 — a thyroid hormone, not a peptide and not a steroid. It is a genuinely FDA-approved prescription drug (since 1956), used mostly as a backup thyroid therapy and misused off-label as a fat-loss agent. The human evidence is strong on two points: adding T3 to T4 does not reliably beat T4 alone for an underactive thyroid, and properly dosed, monitored LT3 has a reassuring safety record, with serious harms almost entirely tied to overdose. In the US it is prescription-only and not a controlled substance, and it is not banned in sport. The real danger is dose-driven thyrotoxicosis — atrial fibrillation, faster bone loss, and strain on the heart — which T3 brings on far more easily than T4, and which is far more likely under unsupervised, off-label use.

Evidence grade: 10/10 · Established. Strong, consistent human evidence on its medical use and on the safety of properly dosed LT3; the harms of non-medical use are well established from large thyrotoxicosis cohorts.

Sources

• FDA Cytomel (liothyronine sodium) Prescribing Information — DailyMed (boxed warning, indications, NDA 010379, 1956 approval)
• Bahl S, et al. 2025 — Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis, J Clin Endocrinol Metab 110(11):3278–3288 (PMID 40795305; DOI 10.1210/clinem/dgaf449)
• Gild ML, et al. 2022 — Thyroid Hormone Abuse in Elite Sports: The Regulatory Challenge, J Clin Endocrinol Metab 107(9):e3562–e3573 (PMID 35438767; DOI 10.1210/clinem/dgac223)
• Collet TH, et al. 2012 — Subclinical Hyperthyroidism and the Risk of Coronary Heart Disease and Mortality, Arch Intern Med 172(10):799–809 (PMID 22529182)
• Blum MR, et al. 2015 — Subclinical Thyroid Dysfunction and Fracture Risk: A Meta-analysis, JAMA 313(20):2055–2065 (PMID 25988595)
• Grozinsky-Glasberg S, et al. 2006 — Thyroxine-Triiodothyronine Combination Therapy Versus Thyroxine Monotherapy for Clinical Hypothyroidism: Meta-Analysis of RCTs, J Clin Endocrinol Metab 91(7):2592–2599
• Fischman A, Domínguez JM 2018 — Combined therapy with levothyroxine and liothyronine for hypothyroidism, Medwave (PMID 30550536)
• WADA — The 2026 Prohibited List PDF (thyroid hormones not prohibited; in force 1 Jan 2026)
• WADA — “WADA’s 2026 Prohibited List is now in force”
• ATSDR — Toxicological Profile for Dinitrophenols (DNP lethality contrast)
• 2,4-Dinitrophenol — overview